Travere Therapeutics names new R&D head ahead of 2027 retirement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026 4:30 PM EDTWilliam Rote, Ph.D., chief research officer plans to retire in early 2027
Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Companys research organization
SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Companys chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the... More
